Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.35 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 2/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1066439 | 0.81 | METAP1 (0.45) | METAP1CA1CA2CYP17A1PSMB8 | |
| SCHEMBL23960291 | 0.77 | ATR (0.43) | METAP1CA1CA2CYP17A1PSMB8 | |
| SCHEMBL13015505 | 0.75 | ATR (0.34) | PAX8LMNAATR | |
| SCHEMBL3039310 | 0.75 | MAPT (0.49) | METAP1CA1CA2CYP17A1PSMB8 | |
| SCHEMBL13015504 | 0.75 | PAX8 (0.34) | PAX8 | |
| SCHEMBL22774998 | 0.74 | CA1 (0.42) | METAP1CA1CA2CYP17A1PSMB8 | |
| SCHEMBL1483110 | 0.74 | CA1 (0.42) | METAP1CA1CA2CYP17A1PSMB8 | |
| SCHEMBL5029628 | 0.73 | PTPN1 (0.56) | METAP1CA1CA2CYP17A1PSMB8 | |
| SCHEMBL15203434 | 0.72 | METAP1 (0.33) | METAP1PAX8CYP17A1PSMB8BRD9 | |
| SCHEMBL9209481 | 0.72 | ATR (0.50) | METAP1CA1CA2CYP17A1PSMB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476278-B2 | Thiazole Derivatives as protein kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20100331313-A1 | Thiazole Derivatives as Protein Kinase Inhibitors | SCHERING CORPORATION | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331313-A1 | Thiazole Derivatives as Protein Kinase Inhibitors | DAPK2, DAPK1, JAK1 | METAP1 1961/4885CA1 2882/4885CA2 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.